Scarica l'app Stockscreener
56.29
0.16%
-0.09
Pre-mercato:
56.68
0.39
+0.69%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
M.E. Allison & CO. Inc. Purchases New Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb Company (BMY): A Bull Case Theory - Yahoo Finance UK
HB Wealth Management LLC Raises Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why Bristol-Myers Squibb (BMY) Is One of the Best Cheap Stocks to Buy for 2025? - Insider Monkey
Trust Co. of Vermont Has $2.55 Million Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Says New Schizophrenia Drug Off to Strong Start - MSN
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Copy of Jim and Mia Cassady Are Bringing Pickleball Centers to Delaware County #2 - BUCKSCO.Today
Bristol-Myers Squibb Company – Consensus ‘hold’ rating and 9.1% Upside Potential - DirectorsTalk Interviews
8,382 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Decker Retirement Planning Inc. - MarketBeat
Eagle Rock Investment Company LLC Lowers Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
8,620 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Contravisory Investment Management Inc. - MarketBeat
Earnings Preview: What To Expect From Bristol-Myers Squibb's Report - Barchart
Cobenfy: Bristol Myers Squibb's Answer to Alzheimer's and SchizophreniaNews and Statistics - IndexBox, Inc.
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug - CNBC
Meyer Handelman Co. Decreases Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Radnor Capital Management LLC Has $4.57 Million Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Acropolis Investment Management LLC Has $1.92 Million Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Leerink Partnrs Analysts Lift Earnings Estimates for BMY - MarketBeat
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol Myers Says New Schizophrenia Drug Off to Strong Start | Company Business News - Mint
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Wright Investors Service Inc. - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Stake Raised by Brookstone Capital Management - MarketBeat
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27) - MSN
Bristol Myers Squibb CEO describes new drug for treating schizophrenia - NBC Philadelphia
Bristol-Myers Squibb (BMY) Releases New Investor Presentation - GuruFocus.com
Mid American Wealth Advisory Group Inc. Decreases Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Capital Investment Advisors LLC Has $14.02 Million Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why Is Intra-Cellular Therapies Surging On Monday?Intra-Cellular Therapies (NASDAQ:ITCI), Johnson & Johnson (NYSE:JNJ) - Benzinga
Czech National Bank Raises Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors - The Manila Times
Bristol Myers Squibb licenses new CAR T therapy - Investing.com
Retinoblastoma Market Profiles: Segment Size, Growth, - openPR
The Bristol Myers Squibb Foundation - Bristol Myers Squibb
Hypercholesterolemia Treatment Market Top PlayersAbbVie, - openPR
West Oak Capital LLC Has $2.28 Million Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? - Benzinga
Franklin Street Advisors Inc. NC Raises Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Abbvie to record $3.5 bln charge related to schizophrenia drug - Reuters
Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference - Benzinga
8 Undervalued Stocks That Just Raised Dividends - Morningstar
How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock - Yahoo Finance
NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries - GlobeNewswire Inc.
International Assets Investment Management LLC Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Car T Cell Therapy Market Investment Opportunities: A Guide to 2031 | Bristol-Myers Squibb Company, Novartis - EIN News
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
114,649 Shares in Bristol-Myers Squibb (NYSE:BMY) Bought by InvesTrust - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Douglas Lane & Associates LLC - MarketBeat
Worth Asset Management LLC Has $583,000 Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Stock Gains 11.4% in a Year: Time to Buy or Sell? - Nasdaq
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo - MSN
Bristol-Myers stock backed by Buy rating as mega-blockbuster potential unfolds - Investing.com India
Bristol-Myers Squibb Company Share Price Target ‘$61.05’, now 7.7% Upside Potential - DirectorsTalk Interviews
Bristol-Myers Squibb (NYSE:BMY) Price Target Raised to $65.00 at Truist Financial - MarketBeat
0.21%
0.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):